Q1 2025 Management View CEO Bernard Zovighian outlined that total company sales grew 8% to $1.41 billion in Q1 2025, driven ...

Shares of Edwards Lifesciences Corp. EW rose 6.63% to $75.13 Thursday, on what proved to be an all-around great trading ...

Canaccord analyst William Plovanic raised the firm’s price target on Edwards Lifesciences (EW) to $75 from $71. The firm said Edwards delivered ...

The heart valve specialist saw better-than-expected TAVR sales in the first quarter as hospitals addressed capacity ...

In a report released today, Matt Miksic from Barclays reiterated a Buy rating on Edwards Lifesciences (EW – Research Report), with a price ...

Edwards Lifesciences stock was flat late Wednesday after the medtech company beat profit views and delivered in-line sales.

Edwards Lifesciences (NYSE: EW) shares stayed put after hours today on first-quarter results that beat Wall Street ...

Edwards Lifesciences raised its 2025 sales forecast on Wednesday after a quarterly beat, driven by robust demand for its artificial heart valves and other medical equipment.

Edwards Lifesciences raised 2025 revenue forecast after Q1 results beat EPS estimates and TMTT sales jumped 58% amid strong ...

Analysts are estimating that Edwards Lifesciences will report an earnings per share (EPS) of $0.59. The announcement from ...

Edwards Lifesciences (EW) announced new eight-year data showing that patients receiving aortic surgical valves treated with its proprietary Resilia tissue technology have significantly improved ...

As Southern California’s life-sciences ecosystem grows, Orange County has become a source of development — but is falling ...